Studysummary This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.
Read the full study on jacionline.org →
Research cited in this study 30
- A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
- Experience with Oral Tofacitinib in Severe Alopecia Areata with Different Clinical Responses Journal of Cosmetic Dermatology · 2021
- An Excellent Response to Tofacitinib in a Brazilian Adolescent Patient with Alopecia Areata: A Case Report and Review of the Literature Clinical Case Reports · 2019
- Experience with Oral Tofacitinib in Adolescents and Adults with Alopecia Areata Dermatologic Therapy · 2019
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases Frontiers in Immunology · 2019
- Treatment of Severe Alopecia Areata with Baricitinib JAAD Case Reports · 2019
- Combination Tofacitinib and Oral Minoxidil Treatment for Severe Alopecia Areata Journal of The American Academy of Dermatology · 2019
- Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases Frontiers in immunology · 2019
- Janus Kinase Inhibitors: An Innovative Treatment for Alopecia Areata Journal of dermatology · 2019
- Alopecia Areata Is Characterized by Dysregulation in Systemic Type 17 and Type 2 Cytokines, Which May Contribute to Disease-Associated Psychological Morbidity British journal of dermatology/British journal of dermatology, Supplement · 2019
- Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study Dermatology · 2018
- High-Throughput T Cell Receptor Sequencing Identifies Clonally Expanded CD8+ T Cell Populations in Alopecia Areata JCI insight · 2018
- An Integrated Model of Alopecia Areata Biomarkers Highlights Both TH1 and TH2 Upregulation Journal of Allergy and Clinical Immunology · 2018
- Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata Drug design, development and therapy · 2018
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis Journal of Investigative Dermatology · 2018
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients International Journal of Trichology · 2018
- Alopecia Areata: Overview and Insights from January 2018 Journal of The American Academy of Dermatology · 2017
- Oral Tofacitinib Monotherapy in Korean Patients with Refractory Moderate-to-Severe Alopecia Areata: A Case Series Journal of the American Academy of Dermatology · 2017
- Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient Skin appendage disorders · 2017
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm Advances in Therapy · 2017
- Excellent Response to Tofacitinib Treatment in a Patient with Alopecia Universalis Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.) · 2017
- Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients Journal of The American Academy of Dermatology · 2016
- Alopecia Areata: What’s New in Epidemiology, Pathogenesis, Diagnosis, and Therapeutic Options? Journal of dermatological science · 2016
- Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata JCI insight · 2016
- Treatment of an Alopecia Areata Patient with Tofacitinib Results in Regrowth of Hair and Changes in Serum and Skin Biomarkers Experimental Dermatology · 2016
- Biomarkers of Alopecia Areata Disease Activity and Response to Corticosteroid Treatment Experimental dermatology · 2015
- Extensive Alopecia Areata Is Reversed by IL-12/IL-23p40 Cytokine Antagonism The Journal of Allergy and Clinical Immunology · 2015
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib EBioMedicine · 2015
- Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
- Alopecia Areata: An Autoimmune Disease Causing Hair Loss The New England Journal of Medicine · 2012